 |
|
|
|
 |
|
|
|
 |
|
|
|
|
|
|
|
BIOCAD is one of the world’s innovative biotechnology companies in Russia. Its leading excellence comes from the world-class R&D centers, modern biotechnological manufacturing facilities, as well as preclinical and clinical research infrastructure that corresponds to the international standards.
BIOCAD is a full-cycle drug development and manufacturing company, ensuring high-quality pharmaceutical development in all stages—from new genetic engineering to large-scale commercial production and further marketing support. The company’s portfolio includes more than 45 marketed products, 10 of them biologics, and over 40 drugs at various stages of development—37 biologics and 8 small molecule compounds. In addition to leading the market with biosimilars and bio-betters, BIOCAD’s focus is on developing original drugs—next-in-class and first-in-class—in immuno-oncology, hematology and autoimmune diseases and other disorders.
BIOCAD is committed to the idea of manufacturing cost-effective drugs as an important cornerstone of strategies to help increase access to biologic medicines in emerging markets as well as in more developed markets such as Europe.
The company employs about 1300 workers, including more than 450 researchers. BIOCAD has created subsidiaries and partnerships in the USA, Brazil, China, India, Vietnam, Egypt and other countries.
www.biocad.ru
|
|
|
|
|
|
|
|
 |
|
|
|
 |
|
|
|
|
|
|
|
|
